Novo Nordisk Cuts Wegovy Prices with New Subscription Plan to Boost U.S. Access

Novo Nordisk has introduced a discounted subscription plan for its blockbuster obesity drug Wegovy in the United States, aiming to expand access for patients paying out of pocket and regain momentum against rival Eli Lilly. The new pricing model offers monthly costs up to nearly 30% lower than the standard rate, as competition intensifies in the rapidly growing obesity-drug market. The move reflects mounting pressure on drugmakers to make treatments more affordable while countering the rise of compounded alternatives.

Under the programme, available through telehealth platforms such as Ro, WeightWatchers and LifeMD, eligible patients can opt for three-, six- or 12-month supply plans, with longer commitments offering greater savings. Wegovy injection pens will be priced at $329 per month for a three-month plan, $299 for six months and $249 for a year-long subscription, compared to the usual $349 monthly cost. The oral version will cost between $289 and $249 per month depending on the plan, marking modest discounts from its standard $299 price.

The strategy comes as Novo Nordisk adapts to shifting consumer behaviour and rising competition, particularly from Eli Lilly’s Zepbound, which has gained traction with competitive pricing and direct-to-consumer sales initiatives. Both companies are increasingly leveraging telehealth and subscription-based models to attract and retain patients, even as deeper price cuts threaten profit margins. Analysts warn that while the approach may widen access, it also signals a growing price war in the obesity treatment market.

Pic Courtesy: google/ images are subject to copyright